Business
Mesoblast reveals more COVID trials needed, shares tumble – Sydney Morning Herald
The Melbourne biotech has been advised by the US medicines regulator that it will need to run another trial of its COVID-19 treatment…
Stem cell treatments maker Mesoblast faces a new hurdle after the US medicines regulator told the company it would need to run another trial of its COVID-19 treatment before it could apply for emergency approvals.
Shares in the Melbourne biotech fell 15.9…
Continue Reading
-
Noosa News24 hours agoHusband charged after beloved Brisbane nurse Carra Luke allegedly stabbed to death in Taigum home
-
Noosa News23 hours agoRallies under way as nationwide support for Palestine surges
-
General23 hours agoTens of thousands protest in nationwide action against war in Gaza
-
General22 hours agoAuthorities say charged man used false name to escape from Perth court